From major journals, first or last author from the Institute for Cancer Research
Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB(2024) IUIS 2023: yEFIS workshop on career development and code-switching Eur J Immunol, e2451155(in press) DOI 10.1002/eji.202451155, PubMed 38676471
Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN(2024) An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer Mol Oncol(in press) DOI 10.1002/1878-0261.13656, PubMed 38671580
Martin KE, Hammer Q, Perica K, Sadelain M, Malmberg KJ(2024) Engineering immune-evasive allogeneic cellular immunotherapies Nat Rev Immunol(in press) DOI 10.1038/s41577-024-01022-8, PubMed 38658708
Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB(2024) IUIS 2023: yEFIS workshop on career development and code-switching Eur J Immunol, e2451155(in press) DOI 10.1002/eji.202451155, PubMed 38676471
Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN(2024) An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer Mol Oncol(in press) DOI 10.1002/1878-0261.13656, PubMed 38671580
Ranji P, Jonasson E, Andersson L, Filges S, Luna Santamaría M, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A(2024) Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development J Transl Med, 22(1), 389 DOI 10.1186/s12967-024-05211-w, PubMed 38671504